A revolutionary injection for chronic obstructive pulmonary disorder (COPD) is being rolled out on the NHS. The jab tackles ...

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes. Objectives: Despite ...

Short-acting bronchodilators offer quick relief of respiratory symptoms, with effects lasting from 30 minutes to several hours. They are often used as a rescue medication. Long-acting bronchodilators ...

Please provide your email address to receive an email when new articles are posted on . The rise in discussion of ventilation support was due to two articles published in the June issue of CHEST being ...

Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for COPD, these inhalers can pose risks ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

Miami (March 4, 2026) – Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors ...